

# Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HDFE7D7A26F6EN.html>

Date: December 2022

Pages: 35

Price: US\$ 2,000.00 (Single User License)

ID: HDFE7D7A26F6EN

## Abstracts

Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Drugs In Development, 2022, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. Symptoms include frequent urination, blurred vision, fatigue headache, nausea and vomiting, dry mouth, coma and confusion. Treatment includes anti-hyperglycemic therapy and insulin therapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperglycemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Unknown stages are 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Hyperglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperglycemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperglycemia (Metabolic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperglycemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Hyperglycemia - Overview

Hyperglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperglycemia - Companies Involved in Therapeutics Development

Auxulin Pharmaceuticals Inc

Boryung Pharmaceutical Co Ltd

FGH BioTech Inc

Guangzhou General Pharmaceutical Research Institute Co Ltd

Protheragen Inc

Hyperglycemia - Drug Profiles

AUX-101 - Drug Profile

Product Description

Mechanism Of Action

Drugs to Inhibit ABHD6 for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

FGH-10019 - Drug Profile

Product Description

Mechanism Of Action

GPCR-targeted Project 014 - Drug Profile

Product Description

Mechanism Of Action

KR-62980 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonise PPARG and Antagonize AGTR1 for Hyperglycemia and

Hypertension - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit SGLT2 for Hyperglycemia and Thrombosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PEPCK for Hyperglycemia - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2

Diabetes - Drug Profile

Product Description

Mechanism Of Action

Hyperglycemia - Dormant Projects

Hyperglycemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hyperglycemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hyperglycemia - Pipeline by Auxulin Pharmaceuticals Inc, 2022

Hyperglycemia - Pipeline by Boryung Pharmaceutical Co Ltd, 2022

Hyperglycemia - Pipeline by FGH BioTech Inc, 2022

Hyperglycemia - Pipeline by Guangzhou General Pharmaceutical Research Institute Co Ltd, 2022

Hyperglycemia - Pipeline by Protheragen Inc, 2022

Hyperglycemia - Dormant Projects, 2022

Hyperglycemia - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hyperglycemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HDFE7D7A26F6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HDFE7D7A26F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

